WP
PVLA

Woodline Partners’s Palvella Therapeutics PVLA Stock Holding History

Woodline Partners’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.6M Buy
317,517
+16,981
+6% +$1.77M 0.15% 178
2025
Q4 		$31.5M Sell
300,536
-45,213
-13% -$3.86M 0.12% 217
2025
Q3 		$21.7M Sell
345,749
-99,866
-22% -$4.45M 0.1% 265
2025
Q2 		$10M Buy
445,615
+251,448
+130% +$5.9M 0.05% 434
2025
Q1 		$5.43M Buy
+194,167
New +$3.74M 0.04% 486
2022
Q2 		– Sell
-19,843
Closed -$4.81M – 905
2022
Q1 		$4.81M Sell
19,843
-10,953
-36% -$2.88M 0.08% 250
2021
Q4 		$9.31M Buy
+30,796
New +$9.86M 0.13% 207
2021
Q2 		– Sell
-6,231
Closed -$1.28M – 635
2021
Q1 		$1.28M Sell
6,231
-8,169
-57% -$1.79M 0.03% 348
2020
Q4 		$2.88M Sell
14,400
-4,759
-25% -$990K 0.08% 183
2020
Q3 		$3.17M Sell
19,159
-1,858
-9% -$423K 0.1% 152
2020
Q2 		$5.21M Buy
21,017
+7,954
+61% +$1.86M 0.21% 111
2020
Q1 		$2.38M Buy
+13,063
New +$3.29M 0.17% 113

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Woodline Partners's PVLA Position: Q1 2026 in Review

Woodline Partners increased its Palvella Therapeutics (PVLA) stake by 5.7% in Q1 2026, buying an estimated $1.77M and bringing the position to 317,517 shares worth $39.6M. The position accounts for 0.15% of the portfolio, ranked #178.

Woodline Partners first reported a position in PVLA in Q1 2020 and has held it in 12 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Woodline Partners held 317,517 shares of Palvella Therapeutics worth $39.6M as of Q1 2026.
  • Woodline Partners bought 16,981 Palvella Therapeutics shares in Q1 2026, an estimated $1.77M.
  • Palvella Therapeutics made up 0.15% of Woodline Partners's portfolio in Q1 2026, its #178 holding.
  • Woodline Partners first reported a position in Palvella Therapeutics in Q1 2020 and has held it in 12 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.